Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Malignant Neoplasm
71%
Maximum Tolerated Dose
70%
Adverse Event
43%
Anticancer Drug
41%
Immunotherapy
40%
Breast Cancer
31%
Progression Free Survival
30%
Tolerability
29%
Diseases
28%
Chemotherapy
27%
Bortezomib
24%
Disease Exacerbation
18%
Anticarcinogen
17%
Neoplasm
15%
Metastatic Uvea Melanoma
15%
Combination Therapy
13%
Overall Survival
12%
Neuropathy
10%
Cabazitaxel
10%
Cisplatin
10%
Erlotinib
9%
Taxane
8%
Cytotoxic Chemotherapy
8%
Triple Negative Breast Cancer
8%
Emphysema
7%
Toxicity
7%
Sotrastaurin
7%
Alpelisib
7%
Propranolol
7%
Fibronectin
7%
Venous Thromboembolism
7%
Premature Labor
7%
Lymph Vessel Metastasis
7%
Placebo
7%
Sitravatinib
7%
Dedifferentiated Liposarcoma
7%
Diffuse Large B Cell Lymphoma
7%
Pexidartinib
7%
Malignant Peripheral Nerve Sheath Tumor
7%
Coronavirinae
7%
Phase II Trials
7%
Phase I Trials
7%
Metformin
7%
Metastatic Colorectal Cancer
7%
Drug Administration
7%
Rituximab
7%
Rapamycin
7%
Transitional Cell Carcinoma
7%
Ruxolitinib
7%
Medicine and Dentistry
Clinical Trial
61%
Breast Cancer
48%
Malignant Neoplasm
44%
Diseases
27%
Overall Survival
26%
COVID-19
22%
Anticancer Drug
22%
Adverse Event
20%
Targeted Therapy
19%
Neoplasm
17%
Lung
17%
Patient-Reported Outcome
15%
Pneumonectomy
15%
Emphysema
14%
Oncology
13%
Reproducibility
12%
Cisplatin
12%
Surgery
12%
Radiation Therapy
12%
Immunotherapy
12%
Metastatic Carcinoma
12%
Drug Prescription
11%
Triple Negative Breast Cancer
11%
Surgeon
11%
Breast Tumor
11%
Progression Free Survival
10%
Quality of Life
10%
Neoadjuvant Chemotherapy
9%
Odds Ratio
9%
Disease Exacerbation
8%
Recurrent Disease
8%
Clinician
8%
Hormone Therapy
8%
Metastatic Breast Cancer
8%
Six Minute Walk Test
8%
Survival Rate
8%
Lymph Node Metastasis
8%
Anticarcinogen
7%
DLCO
7%
Exercise Test
7%
Lumpectomy
7%
Venous Thromboembolism
7%
Cerebrospinal Fluid
7%
Checklist
7%
Intraoperative Radiation Therapy
7%
Rituximab
7%
Pulmonary Fibrosis
7%
Tumor Recurrence
7%
Cytokeratin
7%
Lymphovascular Invasion
7%
Nursing and Health Professions
Adverse Event
16%
Dose Calculation
10%
National Health Organization
10%
Confidence Interval
9%
Cancer Therapy
8%
Malignant Neoplasm
7%
Fibronectin
7%
Lung Fibrosis
7%
Metastatic Breast Cancer
7%
Combination Therapy
7%
Pachymetry
7%
Radiologist
7%
Lung Resection
7%
Cryotherapy
7%
Breast Cancer
7%
Compression Therapy
7%
Central Corneal Thickness
7%
Premature Labor
7%
Placebo
7%
Artificial Tear
7%
Nomenclature
7%
Reflectometry
7%
Neuropathy
7%
Practice Guideline
5%
Maximum Tolerated Dose
5%
Emphysema
5%
Oncologist
5%
Randomization
5%
Interstitial Pneumonia
5%
Functional Status
5%
Chemotherapy-Induced Peripheral Neuropathy
5%
Treatment Outcome
5%
X-Ray Computed Tomography
5%
Drug Dose
5%
Scoring System
5%
Personalized Care
5%
Diseases
5%